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Use of Mechanical Circulatory Support Devices Among Patients
With Acute Myocardial Infarction Complicated by Cardiogenic Shock
Sanket S. Dhruva, MD, MHS; Joseph S. Ross, MD, MHS; Bobak J. Mortazavi, PhD; Nathan C. Hurley, BS; Harlan M. Krumholz, MD, SM; Jeptha P. Curtis, MD;
Alyssa P. Berkowitz, MPH; Frederick A. Masoudi, MD, MSPH; John C. Messenger, MD; Craig S. Parzynski, MS; Che G. Ngufor, PhD; Saket Girotra, MD, SM;
Amit P. Amin, MD, MSc; Nilay D. Shah, PhD; Nihar R. Desai, MD, MPH

Abstract

Key Points

IMPORTANCE Mechanical circulatory support (MCS) devices, including intravascular microaxial left
ventricular assist devices (LVADs) and intra-aortic balloon pumps (IABPs), are used in patients who
undergo percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI) complicated
by cardiogenic shock despite limited evidence of their clinical benefit.

Question What are the trends in the
use of mechanical circulatory support
(MCS) devices, including intravascular
microaxial left ventricular assist devices
(LVADs) and intra-aortic balloon pumps,

OBJECTIVE To examine trends in the use of MCS devices among patients who underwent PCI for
AMI with cardiogenic shock, hospital-level use variation, and factors associated with use.

among patients who underwent
percutaneous coronary intervention for
acute myocardial infarction complicated

DESIGN, SETTING, AND PARTICIPANTS This cross-sectional study used the CathPCI and Chest

by cardiogenic shock?

Pain-MI Registries of the American College of Cardiology National Cardiovascular Data Registry.

Findings In this cross-sectional study of

Patients who underwent PCI for AMI complicated by cardiogenic shock between October 1, 2015, and

28 304 patients, the use of intravascular

December 31, 2017, were identified from both registries. Data were analyzed from October 2018 to

microaxial LVADs increased between

August 2020.

October 2015 and December 2017, with
a corresponding relative decrease in use

EXPOSURES Therapies to provide hemodynamic support were categorized as intravascular

of intra-aortic balloon pumps and

microaxial LVAD, IABP, TandemHeart, extracorporeal membrane oxygenation, LVAD, other devices,

significant hospital-level variation in

combined IABP and intravascular microaxial LVAD, combined IABP and other device (defined as

MCS device use.

TandemHeart, extracorporeal membrane oxygenation, LVAD, or another MCS device), or medical
therapy only.

Meaning Results of this study indicated
that, despite little to no evidence from
clinical trials that demonstrates

MAIN OUTCOMES AND MEASURES Use of MCS devices overall and specific MCS devices, including
intravascular microaxial LVAD, at both patient and hospital levels and variables associated with use.

improved outcomes with use of MCS
devices in the setting of acute
myocardial infarction, persistent use of

RESULTS Among the 28 304 patients included in the study, the mean (SD) age was 65.4 (12.6) years
and 18 968 were men (67.0%). The overall MCS device use was constant from the fourth quarter of
2015 to the fourth quarter of 2017, although use of intravascular microaxial LVADs significantly

MCS devices was observed, including a
substantial increase in intravascular
microaxial LVADs.

increased (from 4.1% to 9.8%; P < .001), whereas use of IABPs significantly decreased (from 34.8%
to 30.0%; P < .001). A significant hospital-level variation in MCS device use was found. The median
(interquartile range [IQR]) proportion of patients who received MCS devices was 42% (30%-54%),
and the median proportion of patients who received intravascular microaxial LVADs was 1%
(0%-10%). In multivariable analyses, cardiac arrest at first medical contact or during hospitalization

+ Supplemental content
Author affiliations and article information are
listed at the end of this article.

(odds ratio [OR], 1.82; 95% CI, 1.58-2.09) and severe left main and/or proximal left anterior
descending coronary artery stenosis (OR, 1.36; 95% CI, 1.20-1.54) were patient characteristics that
were associated with higher odds of receiving intravascular microaxial LVADs only compared with
IABPs only.
(continued)
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Abstract (continued)

CONCLUSIONS AND RELEVANCE This study found that, among patients who underwent PCI for
AMI complicated by cardiogenic shock, overall use of MCS devices was constant, and a 2.5-fold
increase in intravascular microaxial LVAD use was found along with a corresponding decrease in IABP
use and a significant hospital-level variation in MCS device use. These trends were observed despite
limited clinical trial evidence of improved outcomes associated with device use.
JAMA Network Open. 2021;4(2):e2037748. doi:10.1001/jamanetworkopen.2020.37748

Introduction
Intra-aortic balloon pumps (IABPs) have been the mainstay of mechanical circulatory support (MCS)
for patients with cardiogenic shock in the setting of acute myocardial infarction (AMI).1 However,
randomized clinical trial (RCT) data2,3 and subsequent meta-analyses4,5 have reported no clinical
benefit from routine IABP use in patients with AMI complicated by cardiogenic shock. Impella
devices (intravascular microaxial left ventricular assist devices [LVADs]), which offer greater
improvement in hemodynamic parameters compared with IABPs,6 received US marketing clearance
in 2008 for providing partial circulatory support for up to 6 hours using an extracorporeal bypass
control unit and providing circulatory support during procedures not requiring cardiopulmonary
bypass.7 Studies through 2012 showed a substantial uptake of these devices, from 4.6 per million
hospital discharges in 2007 to 138 per million discharges in 2012,8,9 despite the absence of
demonstrated benefits for hard clinical end points in RCTs.6,10 National Cardiovascular Data Registry
(NCDR) records through September 2013 showed that use of MCS devices other than IABP was
clustered around a relatively small number of hospitals but did not increase.9
Despite the substantial risk of death associated with cardiogenic shock11 and the relatively high
cost of some MCS devices,8,12 the temporal and contemporary trends in MCS device use have not
been examined in terms of detailed demographic and clinical characteristics abstracted from medical
records, such as coronary anatomy. Furthermore, previous studies have focused on IABPs and other
MCS devices, providing no granularity about other MCS therapies such as extracorporeal membrane
oxygenation (ECMO). Understanding changes in use as well as the patients likely to receive MCS
devices and the hospitals that are likely to use these devices is particularly important given the recent
safety concerns about intravascular microaxial LVADs.12,13 In this retrospective cross-sectional study,
we collected data from 2 national US registries (of the American College of Cardiology NCDR) to
examine trends in the use of MCS devices, providing greater granularity of the clinical characteristics
and device type than previous studies, among a large cohort of patients who underwent
percutaneous coronary intervention (PCI) for AMI complicated by cardiogenic shock. We also
examined hospital-level use variation and factors associated with use.

Methods
The Human Investigation Committee of the Yale University School of Medicine approved the use of a
limited data set from the NCDR for research purposes without requiring informed consent because
all of the data were deidentified and maintained centrally by the NCDR. This cross-sectional study
followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting
guideline.

Data Sources and Study Population
We linked the NCDR CathPCI and Chest Pain-MI registries, both of which have been described
previously.14,15 In brief, the CathPCI Registry is a voluntary registry of diagnostic cardiac
catheterizations and PCIs performed in the US. More than 1500 hospitals across the US participate
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in this program and are required to submit data on all PCI procedures. The Chest Pain-MI Registry
includes patients with AMI. The CathPCI Registry, version 4.4, identifies whether a patient received
an IABP or any other MCS device and the timing of MCS. Version 2.4.2 of the Chest Pain-MI Registry
data collection form, released in the third quarter of 2015, includes the type of MCS device.
We identified all patients who underwent PCI for AMI complicated by cardiogenic shock
between October 1, 2015, and December 31, 2017, and had available data in both registries. We
included individuals in the Chest Pain-MI Registry who had cardiogenic shock at first medical contact
or as an in-hospital event or individuals in the CathPCI Registry who had cardiogenic shock within 24
hours prior to the PCI, at the start of the PCI, or as an intra- or postprocedure event. Cardiogenic
shock was defined in both registries as systolic blood pressure less than 90 mm Hg and/or cardiac
index lower than 2.2 L/min/m2 for at least 30 minutes that was secondary to ventricular dysfunction
and/or a requirement for parenteral inotropic or vasopressor therapy or MCS devices to support
blood pressure and cardiac index.16 For patients who underwent multiple PCIs during the
hospitalization, we included data from only the initial PCI.

Hemodynamic Support and Covariates
We categorized patients according to the hemodynamic support that they received. The CathPCI
Registry details if a patient received an IABP or a different MCS device. The Chest Pain-MI Registry
details if a patient received an IABP, intravascular microaxial LVAD, TandemHeart (CardiacAssist Inc),
ECMO, LVAD, or other device. The Chest Pain-MI Registry allows documentation of only 1 MCS device
per patient. Therefore, by linking the 2 registries, we could identify the MCS devices used (Chest
Pain-MI Registry) in combination with IABPs (CathPCI Registry). Patients who did not receive any
MCS device composed the medical therapy only group.
Patient-level covariates were patient demographic characteristics, medical history, and clinical
presentation. Hospital-level covariates were number of beds, location, type (government, private, or
university), presence of teaching program, and mean annual PCI volume. For continuous values with
missing values, the mean was imputed. For binary (yes or no) variables, all missing variables were
coded as no; for categorical variables, all missing variables were coded as no or other (if a no category
did not exist).

Statistical Analysis
We characterized overall MCS device use, including for specific sociodemographic and clinical
subgroups (age, sex, race, insurance status, ST-segment elevation MI [STEMI] or non-STEMI, cardiac
arrest or no arrest, and transfer status). We examined trends in the use of hemodynamic support by
calendar quarter using the Cochrane-Armitage test to determine the significance of changes
over time.
We performed multivariable logistic regression to identify independent variables associated
with MCS device use compared with medical therapy among all patients with AMI complicated by
cardiogenic shock, accounting for clustering by facility (ie, accounting for the possible associations
among patients who received care at a given hospital such that the observations were not
independent). The model included demographic variables (age, sex, race, and insurance status),
comorbidities (previous PCI, previous coronary artery bypass graft [CABG], and peripheral artery
disease), clinical presentation variables (cardiac arrest at first medical contact or during
hospitalization, STEMI, anterior infarction, left main or proximal left anterior descending coronary
artery [LAD] disease, and left ventricular ejection fraction), and hospital variables (number of beds,
location, type, teaching program, and mean annual PCI volume). Using the same model, we
performed an additional multivariable logistic regression to examine the odds of a patient receiving
an intravascular microaxial LVAD compared with an IABP, restricting the analyses to patients with
AMI complicated by cardiogenic shock who received either an IABP or intravascular microaxial
LVAD only.
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We examined hospital-level variation in MCS device use among hospitals that cared for at least
10 patients with AMI complicated by cardiogenic shock during the study period. We calculated a
median odds ratio (OR) by building a generalized linear mixed model with random hospital
intercepts. The median OR (always ⱖ1) was derived from the estimate of the variance of the random
intercept of the model.17 Conceptually, the median OR represents the relative odds for 2 identical
patients receiving an MCS device at 1 randomly selected hospital vs another randomly selected
hospital. A median OR of 1.0 indicates no hospital-level variation, whereas a median OR of 2 indicates
that the odds of receiving an MCS device are 2-fold higher in 1 randomly selected hospital vs another
hospital. Using the same methods, we calculated a hospital-specific median OR for a patient with AMI
complicated by cardiogenic shock to receive an intravascular microaxial LVAD.
We compared hospital characteristics (number of beds, location, type, teaching program, and
mean annual PCI volume) by quartiles of MCS device use. We also compared the characteristics of
hospitals that used at least 1 intravascular microaxial LVAD vs hospitals that did not. Among hospitals
that used at least 1 intravascular microaxial LVAD, we compared the characteristics by tertiles. We
used χ2 test for categorical variables and Kruskal-Wallis test for non-normally distributed continuous
variables.
All statistical analyses were 2-sided, with an α = .05 for statistical significance. All analyses were
conducted in R, version 3.6.0 (R Foundation for Statistical Computing), with packages clubSandwich
0.4.218; ggplot2, version 3.2.119; DescTools 0.99.3420; and lubridate 1.7.4.21 Data were analyzed from
October 2018 to August 2020.

Results
MCS Device Use and Change Over Time
Among 28 304 patients with AMI complicated by cardiogenic shock who received PCI at 928
hospitals during the study period, the mean (SD) age was 65.4 (12.6) years and 18 968 were men
(67.0%). Overall, 12 077 patients (42.7%) received an MCS device and 16 227 (57.3%) received
medical therapy only during the hospitalization. Of the 12 077 patients who received an MCS device,
1768 (14.6%) received an intravascular microaxial LVAD only, 8471 (70.1%) received an IABP only, 5
(0%) received TandemHeart, 182 (1.5%) received ECMO, 23 (0.2%) received an LVAD, 276 (2.3%)
received both an IABP and intravascular microaxial LVAD, 4 (0%) received an IABP and
TandemHeart, 138 (1.1%) received an IABP and ECMO, 17 (0.1%) received an IABP and LVAD, and 1193
(9.9%) received another MCS device or a combination of MCS devices (eFigure 1 in the Supplement).
During the study period, the proportion of patients who used any MCS device remained similar
from October through December 2015 to October through December 2017 (from 41.9% to 43.1%;
P = .07) (Figure 1A). A significant increase in the use of intravascular microaxial LVADs (either alone
or in combination with IABPs) was found (from 4.1% to 9.8%; P < .001) during this period along with
a corresponding decrease in the percentage of patients who received IABPs either alone or in
combination with other MCS devices (from 34.8% to 30.0%; P < .001). When limited to patients
receiving any MCS, the use of intravascular microaxial LVADs increased from 9.9% to 20.6%,
whereas IABP use decreased from 83.1% to 73.2% (Figure 1B).

Hospital-Level Variation in MCS Device Use
Of the 928 hospitals included in the study, 521 (56.1%) did not use any intravascular microaxial LVADs
for patients with AMI complicated by cardiogenic shock. Among hospitals with at least 10 cases of
AMI with cardiogenic shock during the study period, a significant variation in MCS device use was
observed (Figure 2). The median (interquartile range [IQR]) proportion of patients who received an
MCS device at the hospital level was 42% (30%-54%; range 4%-94%). The median (IQR) proportion
of patients who received any intravascular microaxial LVAD was 1% (0%-10%; range, 0%-83%).
The hospital-specific median OR for use of any MCS device over the study period was 1.79 (95%
CI, 1.71-1.86). This OR indicates that the odds of receiving an MCS device were 1.79-fold higher in 1
JAMA Network Open. 2021;4(2):e2037748. doi:10.1001/jamanetworkopen.2020.37748 (Reprinted)
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randomly selected hospital vs another. The hospital-specific median OR for use of any intravascular
microaxial LVAD only over the study period was 3.33 (95% CI, 3.03-3.63). This OR indicates that the
odds of receiving an intravascular microaxial LVAD were 3.33-fold higher in 1 randomly selected
hospital vs another.

MCS Device Use by Hospital Characteristics
Among all hospitals that cared for patients with AMI complicated by cardiogenic shock, larger
hospitals (ⱖ600 beds) were more likely to be in higher quartiles of MCS device use and smaller ones
(ⱕ200 beds) were more likely to be in the lowest quartile of MCS device use (Table 1). University
hospitals and those with teaching programs were more likely to be in higher quartiles of MCS device

Figure 1. Quarterly Use of Mechanical Circulatory Support (MCS) Devices for Patients Who Underwent Percutaneous Coronary Intervention (PCI) for
Acute Myocardial Infarction (AMI) Complicated by Cardiogenic Shock From October 2015 to December 2017 at Hospitals Participating in the National
Cardiovascular Data Registry CathPCI and Chest Pain-MI Registries
IABP only
IABP + intravascular microaxial LVAD
ECMO
IABP + other MCS
B

Subset of patients who received an MCS device, with detail about specific
and combinations of MCS devices

100

100

80

80

Percent of patients

Percent of patients

A Patients with AMI complicated by cardiogenic shock who underwent PCI

Intravascular microaxial LVAD only
LVAD
Other or combination MCS
Medical therapy only

60

40

60

40

20

20

0

0
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2016
2016
2016
2017
2017
2017
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2015
2016
2016
2016
2016
2017
2017
2017
2017

Study period

Study period

Patients were categorized according to those receiving an intra-aortic balloon pump (IABP) only, intravascular microaxial left ventricular assist device (LVAD) only, IABP and
intravascular microaxial LVAD, LVAD, extracorporeal membrane oxygenation (ECMO), IABP and other MCS devices, and other MCS devices or combination of MCS devices.

Figure 2. Proportion of Hospitals That Used Mechanical Circulatory Support (MCS) Devices for Patients Who
Underwent Percutaneous Coronary Intervention for Acute Myocardial Infarction Complicated by Cardiogenic
Shock From October 2015 to December 2017
100
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0
Medical therapy
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use. Hospitals with higher mean annual PCI volumes were more likely to use MCS devices. No
significant difference in MCS device use was found across hospitals that were rural, suburban,
or urban.
Hospitals that placed at least 1 intravascular microaxial LVAD for patients who underwent PCI for
AMI complicated by cardiogenic shock were more likely to be large (ⱖ200 beds), be in an urban
setting, have a teaching program, and have a higher annual PCI volume (Table 2). Across tertiles of
hospitals that used intravascular microaxial LVADs, no significant difference was observed in the
number of beds, location, type, or presence of teaching program. Hospitals with lower annual PCI
volume were more likely to be in the highest tertile of intravascular microaxial LVAD use.

MCS Device Use by Patient Demographic and Clinical Characteristics
In comparing the unadjusted use of intravascular microaxial LVADs only with use of IABPs only within
a denominator of all therapies for AMI complicated by cardiogenic shock, men were more likely than
women to receive intravascular microaxial LVADs (6.6% vs 5.4%; P < .01) and IABPs (30.9% vs
27.9%; P < .01) (eFigure 2 in the Supplement). Patients younger than 65 years were more likely to
receive intravascular microaxial LVADs than those aged 75 years or older (6.5% vs 5.4%; P = .002)
(eFigure 3 in the Supplement). Black patients were significantly more likely to receive intravascular
microaxial LVADs compared with patients who were not Black individuals (7.5% vs 6.5%; P = .005)
(eFigure 4 in the Supplement). Additional analyses that characterize the use of MCS devices by
insurance, type of myocardial infarction, cardiac arrest status, and transfer status are provided in
eFigures 5 to 8 in the Supplement.

Characteristics Associated With MCS Device Use and With Intravascular Microaxial
LVAD vs IABP Use
In multivariable regression analysis, female sex (OR, 0.88; 95% CI, 0.83-0.93), the presence of
peripheral artery disease (OR, 0.78; 95% CI, 0.71-0.86), and previous CABG (OR, 0.74; 95% CI, 0.670.81) were associated with lower odds of receiving any MCS device (Table 3). Private insurance (vs
no insurance), cardiac arrest at first medical contact or during hospitalization, STEMI, anterior
infarction, and severe left main and/or proximal LAD stenosis were associated with greater MCS

Table 1. Hospital Characteristics After Stratification by Quartiles of Use of Any
Mechanical Circulatory Support (MCS) Device
Any use of MCS device
Quartile 1
(n = 230)

Quartile 2
(n = 233)

Quartile 3
(n = 229)

Quartile 4
(n = 236)

P value

<29

29 to <42

≥42 to <55

≥55

NA

<200

77 (33.5)

65 (27.9)

47 (20.5)

60 (25.4)

200-399

100 (43.5)

96 (41.2)

91 (39.7)

93 (39.4)

400-599

39 (17.0)

37 (15.9)

51 (22.3)

47 (19.9)

≥600

14 (6.1)

35 (15.0)

40 (17.5)

36 (15.3)

Rural

45 (19.6)

40 (17.2)

36 (15.7)

44 (18.6)

Suburban

79 (34.3)

80 (34.3)

79 (34.5)

81 (34.3)

Urban

106 (46.1)

113 (48.5)

114 (49.8)

111 (47.0)

7 (3.0)

4 (1.7)

3 (1.3)

1 (0.4)

Characteristic
Patients with AMI complicated by
cardiogenic shock who underwent
PCI and received an MCS device at
each hospital, %
Beds, No. (%)

.005

Location

.96

Type
Government

<.001

Private

215 (93.5)

216 (92.7)

195 (85.2)

205 (86.9)

University

8 (3.5)

13 (5.6)

31 (13.5)

30 (12.7)

Teaching program

68 (29.6)

92 (39.5)

104 (45.4)

106 (44.9)

Annual PCI volume, mean (SD)

482.9 (521.4) 546.0 (458.5) 681.0 (644.6) 584.3 (553.4) <.001

.001
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device use. Patients treated at private or university hospitals were more likely to receive any
MCS device.
In multivariable regression analysis, patients who presented with STEMI (OR, 0.69; 95% CI,
0.60-0.80) and with previous CABG (OR, 0.79; 95% CI, 0.64-0.99) had significantly lower odds of
use of intravascular microaxial LVADs only vs use of IABPs only (Table 3). Cardiac arrest at first
medical contact or during hospitalization (OR, 1.82; 95% CI, 1.58-2.09) and severe left main and/or
proximal LAD stenosis (OR, 1.36; 95% CI, 1.20-1.54) were associated with higher odds of intravascular
microaxial LVAD use compared with IABP use.

Discussion
This large, national cross-sectional study of patients who underwent PCI for AMI complicated by
cardiogenic shock showed that, although overall use of MCS devices remained constant between
2015 and 2017, use of intravascular microaxial LVADs increased substantially, whereas use of IABPs
decreased. Significant hospital-level variation in MCS device use was observed, with some hospitals
not using any MCS devices and some hospitals using only intravascular microaxial LVADs or only
IABPs. Other MCS devices remained infrequently used but may be used in combination with or as
part of sequential therapy.
Previous studies through 2013 demonstrated a decrease in IABP use,9 which may be attributed
to RCTs not demonstrating the clinical benefits of this device.2,3 This study extends these past
findings to more recent years. Regardless, we found that IABP remains the most commonly used
MCS device in patients with AMI complicated by cardiogenic shock; more than 70% of patients who
received an MCS device received an IABP. The ongoing use of this device despite its lack of
association with improved clinical outcomes may be explained by familiarity with IABPs and because
clinical practice guidelines in the US have not recommended against routine IABP use.1 This finding
is in contrast to the European Society of Cardiology clinical practice guidelines published in August
2017 (near the end of the study period), which gave routine IABP use a class III recommendation for
patients with cardiogenic shock and STEMI.22

Table 2. Hospital Characteristics After Stratification by Use of Intravascular Microaxial Left Ventricular Assist Device (LVAD)
No use of intravascular
microaxial LVAD
(n = 521)

Any (at least 1) use of intravascular microaxial LVAD
Tertile 1
(n = 125)

Tertile 2
(n = 135)

Tertile 3
(n = 147)

P value
(among tertiles)

P value
(no vs any use)

NA

<7

7 to <15

≥15

NA

NA

.50

<.001

<200

179 (34.4)

16 (12.8)

23 (17.0)

31 (21.1)

200-399

205 (39.3)

54 (43.2)

59 (43.7)

62 (42.2)

400-599

89 (17.1)

30 (24.0)

24 (17.8)

31 (21.1)

≥600

48 (9.2)

25 (20.0)

29 (21.5)

23 (15.6)
.83

.003

Rural

105 (20.2)

18 (14.4)

21 (15.6)

21 (14.3)

Suburban

192 (36.9)

38 (30.4)

38 (28.1)

51 (34.7)

Urban

224 (43.0)

69 (55.2)

76 (56.3)

75 (51.0)
.76

.17

9 (1.7)

1 (0.8)

3 (2.2)

2 (1.4)

Characteristic
Patients with AMI complicated by
cardiogenic shock who underwent PCI
and received an intravascular microaxial
LVAD at each hospital, %
Beds, No. (%)

Location

Type
Government
Private

474 (91.0)

108 (86.4)

120 (88.9)

129 (87.8)

University

38 (7.3)

16 (12.8)

12 (8.9)

16 (10.9)

Teaching program

184 (35.3)

57 (45.6)

69 (51.1)

60 (40.8)

.22

.001

Annual PCI volume, mean (SD)

442.1 (498.1)

821.3 (562.7)

753.4 (666.7)

662.8 (471.2)

.03

<.001

Abbreviations: AMI, acute myocardial infarction; NA, not applicable; PCI, percutaneous coronary intervention.
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The increasing use of intravascular microaxial LVADs may be associated with the greater
hemodynamic support they provide compared with IABPs to patients with cardiogenic shock,6 who
have a high mortality risk. Patients expected to have greater hemodynamic compromise, including
those with cardiac arrest and left main or proximal LAD disease, were more likely to receive

Table 3. Patient and Hospital Characteristics Associated With Use of Any Mechanical Circulatory Support (MCS)
Device vs Medical Therapy Only and With Use of Intravascular Microaxial Left Ventricular Assist Device (LVAD)
Only vs Intra-Aortic Balloon Pump Only
OR (95% CI)
Use of any MCS drvice vs
medical therapy only

Use of intravascular microaxial LVAD vs
intra-aortic balloon pump

Age

1.00 (1.00-1.00)

1.00 (0.99-1.00)

Female sex

0.88 (0.83-0.93)

0.93 (0.82-1.05)

BMI

1.01 (1.00-1.01)

1.02 (1.01-1.03)

Variable
Patient characteristics

Race
Othera

1 [Reference]

1 [Reference]

White

0.88 (0.77-1.00)

1.04 (0.75-1.46)

Black

0.86 (0.74-1.00)

1.29 (0.86-1.94)

Insurance
None

1 [Reference]

1 [Reference]

Medicaid

1.06 (0.92-1.22)

0.87 (0.64-1.16)

Medicare

1.11 (0.99-1.24)

0.93 (0.73-1.18)

Private

1.13 (1.03-1.23)

1.00 (0.81-1.24)

Medicaid and Medicare

0.97 (0.84-1.13)

0.91 (0.65-1.28)

Private and public

1.06 (0.94-1.18)

0.94 (0.74-1.20)

Other or combined with other
insurance

1.07 (0.93-1.24)

1.05 (0.79-1.39)

Medical history
PAD

0.78 (0.71-0.86)

1.26 (1.05-1.52)

Cardiac arrest at first medical contact
or during hospitalization

1.70 (1.58-1.83)

1.82 (1.58-2.09)

STEMI

1.19 (1.11-1.28)

0.69 (0.60-0.80)

Anterior infarction

1.19 (1.12-1.27)

0.94 (0.82-1.07)

Left main or proximal LAD disease

2.21 (2.08-2.35)

1.36 (1.20-1.54)

Previous PCI

1.00 (0.94-1.07)

1.04 (0.92-1.18)

Previous CABG

0.74 (0.67-0.81)

0.79 (0.64-0.99)

LVEF (per 1% increase)

0.96 (0.96-0.97)

0.97 (0.97-0.98)

Hospital characteristics
No. of beds
<200

1 [Reference]

1 [Reference]

200-399

1.09 (0.94-1.27)

1.04 (0.65-1.65)

400-599

1.13 (0.94-1.35)

0.98 (0.61-1.57)

≥600

1.22 (0.99-1.50)

0.81 (0.48-1.39)

Location
Rural

1 [Reference]

1 [Reference]

Suburban

0.91 (0.77-1.08)

0.86 (0.55-1.37)

Urban

0.89 (0.75-1.05)

1.08 (0.70-1.66)

Teaching program

1.02 (0.91-1.15)

1.05 (0.79-1.39)

Abbreviations: BMI, body mass index (calculated as
weight in kilograms divided by height in meters
squared); CABG, coronary artery bypass graft; LAD,
left anterior descending coronary artery; LVEF, left
ventricular ejection fraction; OR, odds ratio; PAD,
peripheral artery disease; PCI, percutaneous coronary
intervention; STEMI, ST-segment elevation myocardial
infarction.

Mean annual PCI volume (per increase
of 1 annual PCI)

1.00 (1.00-1.00)

1.00 (1.00-1.00)

a

Type
Government

1 [Reference]

1 [Reference]

Private

1.33 (0.80-2.21)

0.91 (0.44-1.85)

University

1.84 (1.08-3.12)

0.82 (0.36-1.90)
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intravascular microaxial LVADs. Some groups have recommended intravascular microaxial LVADs for
patients with severe cardiogenic shock.23
However, the significant hospital-level variation in MCS device use and intravascular microaxial
LVAD use suggests that no standard of care exists. This lack of consensus is consistent with multiple
other studies, including a study of patients with AMI complicated by cardiogenic shock that reported
that patient characteristics were not associated with MCS device use24 and with another study of
patients with cardiogenic shock in cardiac intensive care units in which hospital-level variation in MCS
device use could not be explained by differences in illness severity.25
One reason for the substantial variation in hospital use of MCS devices may be the paucity of
clinical study data demonstrating the clinical benefit of intravascular microaxial LVAD use among
patients with AMI complicated by cardiogenic shock.26 Existing RCTs do not show the benefits of
IABP use in AMI with cardiogenic shock,6,10 although recent large observational studies have found
that intravascular microaxial LVAD use was associated with higher mortality compared with IABP
use.12,13 Intravascular microaxial LVADs were also significantly more expensive than IABPs,
suggesting significant differences in total cost.8,12,27 Another reason for the variation in hospital-level
device use could be that patient and device selection for AMI with cardiogenic shock remains
uncertain because of the clinical heterogeneity of cardiogenic shock.11 A recently released
classification scheme28 could help establish the specific cardiogenic shock stages under which
different MCS devices should be deployed. A third reason for the hospital-level use variation may be
that hospitals that have invested in the infrastructure to deploy intravascular microaxial LVADs for
the care of patients are more likely to use these devices. Differences in reimbursement for
intravascular microaxial LVADs vs IABPs8 as well as other factors may also be associated with the
observed use trends. Additional RCT evidence, which would help guide the selection, use, and timing
of MCS devices in patients with AMI complicated by cardiogenic shock, could play a role in reducing
hospital-level variation and improving patient outcomes as well as targeting these devices to patients
who are most likely to find them beneficial.26,29
Among patients with STEMI, we found increased odds of MCS device use but lower use of
intravascular microaxial LVADs. Because patients with STEMI in general have more acute, unstable
presentations and are more likely to have a cardiac arrest, it is not surprising that these patients often
received MCS devices. However, in the model adjusted for clinical presentation and coronary
anatomy, the lower odds of intrasvascular microaxial LVAD vs IABP use broadly highlighted the
substantial variation in use trends that seemed to be associated not only with clinical presentation or
physiological features but also with discretionary decision-making by physicians and institutions.
A novel finding of this study was that women with AMI complicated by cardiogenic shock were
less likely than men to receive any MCS therapy. This finding extends the reports of differences in
treatment provided to women with AMI, such as primary PCI30 and other device-based therapy for
cardiovascular disease.31 These differences may be associated with the smaller vascular anatomy,
which cannot accommodate the large bore access needed for MCS devices, and a greater
predisposition to bleeding complications in women compared with men.32 Further research is
needed to ascertain the reasons for these sex-based differences.

Limitations
This study has several limitations. First, the presence of cardiogenic shock was based on site
documentation. Second, different types of intravascular microaxial LVADs, specifically the Impella
2.5, CP, 5.0, and RP devices (ABIOMED), could not be distinguished. Third, because the Chest Pain-MI
Registry allows only a single MCS device to be coded, some patients may have received combinations
of devices that were not captured. Fourth, we did not have information on all variables relevant to
cardiogenic shock (eg, lactate levels or number of vasopressors used), which may be associated with
use of specific MCS devices.
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Conclusions
Among patients who underwent PCI for AMI complicated by cardiogenic shock from October 2015
to December 2017, use of intravascular microaxial LVADs increased, with a corresponding decrease in
use of IABPs despite limited clinical trial evidence of improved outcomes associated with device use.
Significant hospital-level variation in use of MCS devices was also found.
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